Resistance to farnesyltransferase inhibitors in Bcr/Abl sorted by
relevance

Admin13.09.2021

Resistance to farnesyltransferase inhibitors in Bcr/Abl

3909
Admin29.09.2021

Increased resistance to a farnesyltransferase inhibitor by

4609
Admin14.09.2021

CML stem cells are resistant to BCR-ABL kinase inhibitor

408
Admin21.07.2021

The coupleable analogues of the BCR-ABL inhibitors retain

4709
Admin26.08.2021

Flying under the radar: the new wave of BCR-ABL inhibitors

6804
Admin23.08.2021

Figure 1 from Second generation inhibitors of BCR-ABL for

Admin14.08.2021

Rapid induction of resistance to BCR-ABL kinase inhibitors

7006
Admin09.08.2021

Figure 1 from BCR-ABL kinase domain mutation analysis in

5705
Admin01.10.2021

Characteristics of imatinib-resistant patients according

Admin14.07.2021

The Growing Arsenal of ATP-Competitive and Allosteric

2006
Admin01.08.2021

Targeting the BCR-ABL Signaling Pathway in Therapy

6405
Admin09.10.2021

A farnesyltransferase inhibitor increases survival of mice

Admin27.08.2021

Figure 1 from Mechanisms of Resistance to ABL Kinase

2302
Admin14.07.2021

Leukemia Fighter! (CML); I Am Dancing and Traveling My Way

300
Admin09.08.2021

BCR-ABL inhibitor asciminib (ABL001) meets phase 3 primary

Admin08.08.2021

STI571: an inhibitor of the BCR-ABL tyrosine kinase for

6010
Admin16.07.2021

Resistance to farnesyltransferase inhibitors in Bcr/Abl

1107
Admin15.07.2021

Inhibitors of Bcr-abl breaking new ground again

801
Admin04.10.2021

(PDF) Combination treatment of imatinib-sensitive and

8507
Admin04.10.2021

Past, present, and future of Bcr-Abl inhibitors: from

8504
Admin27.09.2021

(PDF) Bcr-Abl-Independent Imatinib-Resistant K562 Cells

3504